Latest & greatest articles for corticosteroids

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on corticosteroids or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on corticosteroids and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for corticosteroids

741. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. (Abstract)

Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Asthma self-management plans that include doubling the dose of inhaled corticosteroid when the condition deteriorates improve asthma control. Whether doubling the dose of corticosteroid in isolation is effective is unknown. We undertook a randomised controlled trial to investigate the effects of doubling the dose of inhaled corticosteriods when asthma deteriorates.390 individuals (...) with asthma who were at risk of an exacerbation monitored their morning peak flow and asthma symptoms for up to 12 months. When peak flow or symptoms started to deteriorate, participants added an active or placebo corticosteroid inhaler to their usual corticosteroid for 14 days to produce a doubling or no change in dose. The primary outcome was the number of individuals starting oral prednisolone in each group.During 12 months, 207 (53%) started their study inhaler and 46 (12%) started prednisolone--22

2004 Lancet Controlled trial quality: predicted high

742. Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation

Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review (...) and economic evaluation Green C, Colquitt J L, Kirby J, Davidson P, Payne E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Green C, Colquitt J L, Kirby J, Davidson P, Payne E. Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation

2004 Health Technology Assessment (HTA) Database.

743. Frequency of application of topical corticosteroids for atopic eczema

Frequency of application of topical corticosteroids for atopic eczema Frequency of application of topical corticosteroids for atopic eczema Frequency of application of topical corticosteroids for atopic eczema National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Frequency (...) of application of topical corticosteroids for atopic eczema. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 81. 2004 Authors' objectives To provide guidance on the frequency of application of topical corticosteroids for atopic eczema. Authors' conclusions This appraisal relates to the frequency of application of topical corticosteroids in the treatment of atopic eczema. It does not include the use of topical agents that combine corticosteroids with other

2004 Health Technology Assessment (HTA) Database.

744. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis

Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2004 PedsCCM Evidence-Based Journal Club

745. Thyrotropin-releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. (Abstract)

Thyrotropin-releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. Thyrotropin-releasing hormones (TRH) added to prenatal corticosteroids has been suggested as a way to further reduce breathing problems and neonatal lung disease in infants born preterm.To assess the effect of giving prenatal TRH in addition to corticosteroids to women at risk of very preterm birth for the prevention of neonatal respiratory disease.We searched (...) the Cochrane Pregnancy and Childbirth Group trials register (July 2003), the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 3, 2003), MEDLINE (1965 to July 2003), EMBASE (1988 to July 2003), Current Contents (1997 to July 2003).Randomised controlled trials in women at sufficient risk of preterm birth to warrant the use of prenatal corticosteroids to promote lung maturity. TRH and corticosteroids were compared with corticosteroids with or without placebo. The main outcomes

2004 Cochrane

746. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Full Text available with Trip Pro

Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Anti-leukotrienes agents are currently being studied as alternative first line agents to inhaled corticosteroids in mild to moderate chronic asthma.To compare the safety and efficacy of anti-leukotriene agents with inhaled glucocorticoids (ICS) and to determine the dose-equivalence of anti-leukotrienes to daily dose of ICS.We searched MEDLINE (1966 to Aug 2003 (...) ), EMBASE (1980 to Aug 2003), CINAHL (1982 to Aug 2003), the Cochrane Airways Group trials register, and the Cochrane Central Register of Controlled Trials (August 2003), abstract books, and reference lists of review articles and trials. We contacted colleagues and international headquarters of anti-leukotrienes producers.Randomised controlled trials that compared anti-leukotrienes with inhaled corticosteroids during a minimal 30-day intervention period in asthmatic patients aged 2 years and older.Two

2004 Cochrane

747. Corticosteroids for HELLP syndrome in pregnancy. (Abstract)

Corticosteroids for HELLP syndrome in pregnancy. Hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome is a severe form of pre-eclampsia. Pre-eclampsia is a multi-system disease of pregnancy associated with an increase in blood pressure and increased perinatal and maternal morbidity and mortality. Eighty per cent of women with HELLP syndrome present before term. There are suggestions from observational studies that steroid treatment in HELLP syndrome may improve disordered (...) maternal hematological and biochemical features and perhaps perinatal mortality and morbidity.To summarise the evidence on the effects of corticosteroids on maternal and neonatal mortality and morbidity in women with HELLP syndrome.We searched the Cochrane Pregnancy and Childbirth Group trials register (October 2003). We scanned lists of references from review articles and primary studies.Randomised and quasi-randomised trials evaluating the effects of adjunctive corticosteroids in patients diagnosed

2004 Cochrane

748. Corticosteroids for treating severe sepsis and septic shock. (Abstract)

Corticosteroids for treating severe sepsis and septic shock. Sepsis may be complicated by impaired corticosteroid production. Giving corticosteroids could potentially benefit patients.To examine the effects of corticosteroids on death at one month in patients with severe sepsis and septic shock.We searched the Cochrane Infectious Diseases Group's trial register (August 2003), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 3, 2003), MEDLINE (August 2003 (...) ), EMBASE (August 2003), LILACS (August 2003), reference lists of articles, and also contacted trial authors.Randomized and quasi-randomized controlled trials of corticosteroids versus placebo or supportive treatment in severe sepsis and septic shock.Two pairs of reviewers agreed the eligibility of trials. One reviewer extracted data, which was checked by the other reviewers and the primary author of the paper whenever possible. We obtained some missing data from the trial authors. We assessed trial

2004 Cochrane

749. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. (Abstract)

Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Duchenne muscular dystrophy is the most common muscular dystrophy of childhood. This incurable disease is characterised by muscle wasting and loss of walking ability leading to complete wheelchair dependence by 13 years of age. Prolongation of walking is one of the major aims of treatment.The aim of this review was to assess whether glucocorticoid corticosteroids stabilize or improve muscle strength and walking in boys with DMD.We (...) controlled trials that met the inclusion criteria for our review. Two reviewers independently selected the trials for the review and assessed methodological quality. Data extraction and inputting were double-checked.data from one small study used prolongation of walking as an outcome measure and did not show significant benefit.The meta-analysis of the results from three randomised controlled trials showed that glucocorticoid corticosteroids improved muscle strength and function over six months

2004 Cochrane

750. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. Full Text available with Trip Pro

High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. Inhaled corticosteroids (ICS) form the basis of maintenance therapy in asthma and their efficacy is well established. However, the optimal starting dose of ICS is not clearly established. Recent reviews demonstrate a relatively flat efficacy curve for ICS and increasing side effects with increasing ICS doses. High doses are frequently prescribed and there are now reports of significant

2004 Cochrane

751. Azathioprine as an oral corticosteroid sparing agent for asthma. (Abstract)

Azathioprine as an oral corticosteroid sparing agent for asthma. For the majority of chronic asthmatics, symptoms are best controlled by using inhaled steroids. However, for a small group of asthmatics, symptoms can only be controlled by high doses of oral steroids. Continuous use of oral steroid is associated with severe side-effects, but it has been suggested that azathioprine, an immunosuppressive anti-metabolite, often used to reduce the immune response in chronic active hepatitis (...) and severe rheumatoid arthritis, could be useful as an oral steroid sparing agent. There is a need to systematically evaluate the evidence regarding its use to reduce or eliminate oral corticosteroid usage.The objective of this review is to assess the efficacy of adding azathioprine in patients with stable asthma who are dependent on oral corticosteroids with the intention of eventually minimizing or eliminating the use of these steroids.Searches of the Cochrane Airways Group asthma and wheeze trials

2004 Cochrane

752. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. Full Text available with Trip Pro

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. Severe acute respiratory syndrome (SARS) is a new clinical entity for which no effective therapeutic strategy has been developed.To provide preliminary results on the potential therapeutic benefit and tolerability of interferon alfacon-1 plus corticosteroids for SARS.Open-label study of 22 patients diagnosed as having probable SARS at North York General Hospital, Toronto, Ontario, between April (...) 11 and May 30, 2003.Thirteen patients were treated with corticosteroids alone and 9 patients were treated with corticosteroids plus subcutaneous interferon alfacon-1.Clinical parameters, including oxygen saturation and requirement, laboratory measures, and serial chest radiography results.Resolution of fever and lymphopenia were similar between the 2 treatment groups. Of the 13 patients treated with corticosteroids alone, 5 (38.5%) were transferred to the intensive care unit, 3 (23.1%) required

2003 JAMA

753. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis

Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis Sutherland E R, Allmers H, Ayas N T, Venn A J, Martin R J CRD summary This review assessed inhaled corticosteroids (...) in patients with chronic obstructive pulmonary disease (COPD). The authors concluded that treatment with inhaled corticosteroids for at least two years slows the rate of decline in lung function in patients with COPD. The authors' conclusions are likely to be reliable. Authors' objectives To assess the effects of inhaled corticosteroids (ICS) on the progression of airflow limitation in patients with chronic obstructive pulmonary disease (COPD). Searching MEDLINE (from 1966 to February 2003), CINAHL (from

2003 DARE.

754. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma

Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma Leone FT, Fish JE, Szefler SJ, West SL CRD summary This review evaluated the evidence regarding complications of inhaled corticosteroid (ICS) use in people with asthma (...) . The authors concluded that the clinical effectiveness of ICS treatment clearly outweighs the risks. The authors' conclusions are in line with the evidence they present. However, the validity of the authors' conclusions are limited by selective presentation of only part of the available evidence. Authors' objectives To critically evaluate the strength and direction of the available evidence on the complications of inhaled corticosteroid (ICS) use in patients with asthma. Searching Randomised controlled

2003 DARE.

755. A systematic review of the adjunctive use of systemic corticosteroids for pulmonary tuberculosis

A systematic review of the adjunctive use of systemic corticosteroids for pulmonary tuberculosis A systematic review of the adjunctive use of systemic corticosteroids for pulmonary tuberculosis A systematic review of the adjunctive use of systemic corticosteroids for pulmonary tuberculosis Smego R A, Ahmed N CRD summary This review assessed adjunctive systemic corticosteroids in the treatment of pulmonary tuberculosis (PTB). The authors concluded that adjunctive systemic corticosteroids can (...) safely provide significant clinical and radiologic benefits for selected patients with advanced PTB. Since most of the included studies were conducted over 20 years ago, the relevance of the results to current practice is unknown. Authors' objectives To assess the safety and benefits of adjunctive systemic corticosteroids in the treatment of pulmonary tuberculosis (PTB). Searching MEDLINE, Index Medicus and Current Contents were searched to 2001 for studies published in English; the keywords were

2003 DARE.

756. The use of corticosteroids versus other treatments for Graves' ophthalmopathy: a quantitative evaluation

The use of corticosteroids versus other treatments for Graves' ophthalmopathy: a quantitative evaluation The use of corticosteroids versus other treatments for Graves' ophthalmopathy: a quantitative evaluation The use of corticosteroids versus other treatments for Graves' ophthalmopathy: a quantitative evaluation Abalkhail S, Doi S A, Al-Shoumer K A CRD summary This review assessed the use of corticosteroids in the treatment of Graves' ophthalmopathy. The authors concluded that oral (...) corticosteroids administered in combination with radiotherapy, and intravenous corticosteroids with or without radiotherapy, were the most effective treatments. Given the lack of a quality assessment, and the pooling of different outcome measures and study designs, the conclusions should be viewed cautiously. Authors' objectives To assess the efficacy of corticosteroids, compared with other treatments, for the treatment of Graves' ophthalmopathy. Searching MEDLINE was searched from 1966 to 2001; the search

2003 DARE.

757. Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis

Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis Currie G P, Fowler S J, Lipworth B J CRD summary This review assessed the relationship between inhaled corticosteroid dose and bronchial hyperresponsiveness in patients with asthma. The authors concluded that high doses (...) conferred greater improvements than low doses. The conclusions appear to follow from the evidence presented but it is difficult to comment on their reliability because of methodological and reporting limitations in the review. Authors' objectives To determine whether a dose-response effect exists between inhaled corticosteroids and bronchial hyper-responsiveness (BHR) in asthmatic patients. Searching MEDLINE, databases on BIDS, and the Cochrane Library were searched up to May 2001; the search terms were

2003 DARE.

758. Airway-stabilizing effect of long-acting beta2-agonists as add-on therapy to inhaled corticosteroids

Airway-stabilizing effect of long-acting beta2-agonists as add-on therapy to inhaled corticosteroids Airway-stabilizing effect of long-acting beta2-agonists as add-on therapy to inhaled corticosteroids Airway-stabilizing effect of long-acting beta2-agonists as add-on therapy to inhaled corticosteroids Currie G P, Jackson C M, Ogston S A, Lipworth B J CRD summary This review assessed the bronchoprotective effects of salmeterol or formeterol in patients with asthma who were using corticosteroid (...) University of Dundee. Bibliographic details Currie G P, Jackson C M, Ogston S A, Lipworth B J. Airway-stabilizing effect of long-acting beta2-agonists as add-on therapy to inhaled corticosteroids. QJM: an International Journal of Medicine 2003; 96(6): 435-440 Indexing Status Subject indexing assigned by NLM MeSH Adrenal Cortex Hormones /therapeutic use; Adrenergic beta-Agonists /therapeutic use; Albuterol /analogs & Asthma /prevention & Bronchodilator Agents /therapeutic use; Ethanolamines /therapeutic

2003 DARE.

759. Effects of a single course of corticosteroids given more than 7 days before birth: a systematic review

Effects of a single course of corticosteroids given more than 7 days before birth: a systematic review Effects of a single course of corticosteroids given more than 7 days before birth: a systematic review Effects of a single course of corticosteroids given more than 7 days before birth: a systematic review McLaughlin K J, Crowther C A, Walker N, Harding J E CRD summary This review concluded that exposure to a single course of prenatal corticosteroids administered more than 7 days before birth (...) does not reduce the incidence of respiratory distress syndrome, but can increase the risk of perinatal mortality, earlier birth and maternal infectious morbidity. The review was generally well-conducted and, despite a few methodological considerations, the conclusions are likely to be reliable. Authors' objectives To determine the effects of a single course of prenatal corticosteroids administered more than 7 days before birth on foetal, neonatal and maternal mortality and morbidity. Searching

2003 DARE.

760. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease: a meta analysis

Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease: a meta analysis Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease: a meta analysis Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease: a meta analysis Highland K B, Strange C, Heffner J E CRD summary This review evaluated the long-term effects of inhaled corticosteroids (...) in patients with chronic obstructive pulmonary disease (COPD). It found that inhaled corticosteroids did not modify the long-term decline in lung function associated with COPD. This was a well-conducted review and, provided the primary randomised controlled trials are of reasonable quality, the authors' conclusions regarding long-term outcomes with inhaled corticosteroids appear reliable. Authors' objectives To evaluate the long-term effects of inhaled corticosteroids on the rate of forced expiratory

2003 DARE.